Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cyclopharm Limited ( (AU:CYC) ) has shared an announcement.
Cyclopharm Limited has announced that director Kevin Michael John Barrow ceased to be a director of the company on 8 May 2026, with the disclosure lodged under ASX listing rule obligations. The filing also notes that while Barrow holds no shares directly, an associated trust linked to his wife, the Melissa Elizabeth Barrow Trust via BT Panorama Investments, holds 30,347 fully paid ordinary shares, indicating ongoing indirect exposure to the company’s equity despite his board departure.
The notice confirms that Barrow has no disclosed interests in contracts with the company at the time of his resignation, limiting potential concerns about related-party arrangements following his exit. For investors and governance watchers, the change marks a board refresh while signalling that a portion of Barrow’s economic interest in Cyclopharm remains aligned with shareholders through the family trust’s holdings.
The most recent analyst rating on (AU:CYC) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited is an Australia-listed healthcare company operating in the medical technology and pharmaceutical sector. It is focused on diagnostic and therapeutic products, with its securities traded on the ASX and governed by Australian corporate and listing rules.
Average Trading Volume: 122,155
Technical Sentiment Signal: Sell
Current Market Cap: A$92.66M
See more data about CYC stock on TipRanks’ Stock Analysis page.